Advertisement
"We are very excited that our Jiangling plant has successfully obtainedthe GMP certificate. This certificate represents the endorsement of ourquality control system and production facilities by the SFDA, and is a majorstep to launch and market our Ribavrin in the domestic market," stated CharlesWan, Chief Executive Officer of Benda Pharmaceutical.
Advertisement
Jiangling Benda plans to produce four types of Active PharmaceuticalIngredients (APIs), including Ribavrin, Asarin, Levofloxacin Mesylate andRibose. The production of the APIs, with the exception of Ribose, requires GMPcertification. The Jiangling plant was closed for renovation in July 2004 tocomply with GMP standards and was reopened in August 2007 for the productionof Ribose. It currently has all of the production equipment in place, and thenew facilities have been installed and tested for Ribavrin and Ribose.
Additional information regarding this certificate, issued on April 9, 2008,can be found on the SFDA website ( http://www.sfda.gov.cn ).
About Jiangling Benda
Jiangling Benda develops, manufactures and sells Active PharmaceuticalIngredients ("APIs"), which are one of the two components of any capsules,tablets and fluids that are pharmaceutically active. An API is the substancein a drug that produces the desired medicinal effect. The "excipient" is theinert material that holds the API (such as gelatin or water). About 3.7 percent of the APIs that Jiangling Benda produced in 2004 were used to producesome of the company's finished medicines. The remainder was sold in the marketto unrelated parties. Jiangling Benda did not sell to related Benda companiesin 2006 or 2007.
About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-basedpharmaceutical company, produces traditional Chinese and conventionalmedicines, as well as Gendicine(R), a commercialized gene therapy medicine forthe treatment of cancer.
Safe Harbor Statement
The information contained herein includes forward-looking statements.These statements relate to future events or to our future financialperformance, and involve known and unknown risks, uncertainties and otherfactors that may cause our actual results, levels of activity, performance, orachievements to be materially different from any future results, levels ofactivity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-lookingstatements since they involve known and unknown risks, uncertainties and otherfactors which are, in some cases, beyond our control and which could, andlikely will, materially affect actual results, levels of activity, performanceor achievements. Any forward-looking statement reflects our current views withrespect to future events and is subject to these and other risks,uncertainties and assumptions relating to our operations, results ofoperations, growth strategy and liquidity. We assume no obligation to publiclyupdate or revise these forward-looking statements for any reason, or to updatethe reasons actual results could differ materially from those anticipated inthese forward-looking statements, even if new information becomes available inthe future. The safe harbor for forward-looking statements contained in theSecurities Litigation Reform Act
